Wednesday, December 13, 2023 6:11:34 AM
Third Quarter 2023 Financial Summary Compared to Second Quarter 2023,
Total net revenue increased 48% to $1,162,631, compared to $786,489
? Operating expenses decreased 24% to $535,860, compared to $707,529
? Net loss decreased 40% to $215,065, compared to $359,766
? Operating income of $88,819, compared to operating loss of $405,819
? Total Liabilities decreased 16% to $9,255,638, compared to $11,005,895
$CMGR
Management Commentary
“We are pleased with the overall results this quarter”, said Amir Ben-Yohanan, CEO of CMGR. “Our revenue has significantly increased and we managed to decrease the total debt from last quarter. We’re excited about the growth potential for both our digital agency and our creator monetization platform.”
“I think this was a successful quarter” added Scott Hoey, Chief Financial Officer of CMGR. “We managed to increase our revenue and decrease our expenses once again. We are working hard to continue this trajectory throughout Q4.”
https://www.otcmarkets.com/filing/html?id=17042926&guid=3dJ-kWsDF2Enzrh#ex99-1_htm
Recent CMGR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:37:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:35:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:34:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:32:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:29:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:25:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:23:59 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 02:22:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 01:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:00:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 01:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 12:30:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2023 09:36:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 12:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 12:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:35:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM